Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 10Terminated 4Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Uveal Melanoma 1Stomach Neoplasms 1Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × ADI PEG20 × Clear all
NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Polaris Group

Phase 1 Terminated
33 enrolled

Advanced Solid Cancers

NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

NCT02875093 2020-03-05

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Polaris Group

Phase 1 Terminated
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡